P09-02. Selection pressure of neutralizing antibodies and viral escape continues in late stages of the disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-4690
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
P09-02. Selection pressure of neutralizing antibodies and viral escape continues in late stages of the disease ; volume:6 ; number:3 ; day:22 ; month:10 ; year:2009 ; pages:1 ; date:10.2009
Retrovirology ; 6, Heft 3 (22.10.2009), 1, 10.2009
- Creator
-
Rusert, P.
- Contributor
-
Krarup, A.
Joos, B.
Uhr, T.
Weber, J.
Herbert, K.
Guenthard, HF
Trkola, Alexandra
SpringerLink (Online service)
- DOI
-
10.1186/1742-4690-6-S3-P115
- URN
-
urn:nbn:de:1111-201608079307
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rusert, P.
- Krarup, A.
- Joos, B.
- Uhr, T.
- Weber, J.
- Herbert, K.
- Guenthard, HF
- Trkola, Alexandra
- SpringerLink (Online service)
Other Objects (12)
P03-07. Autologous neutralizing antibodies that select viral escape variants emerge late after SIV infection of rhesus monkeys
Identification and characterization of broadly neutralizing antibodies targeting viral infections
P09-12. Autologous neutralizing antibodies in early subtype C HIV-1 infection target variable regions of envelope and drive multiple pathways of viral escape
Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies
Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies
Broadly Neutralizing Antibodies for HIV Eradication
Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
Adapting Neutralizing Antibodies to Viral Variants by Structure‐Guided Affinity Maturation Using Phage Display Technology
Retracted: Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies
Non-neutralizing antibodies and vaccine-induced protection
Eliciting neutralizing antibodies with gp120 outer domain
How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin
P03-07. Autologous neutralizing antibodies that select viral escape variants emerge late after SIV infection of rhesus monkeys
Identification and characterization of broadly neutralizing antibodies targeting viral infections
P09-12. Autologous neutralizing antibodies in early subtype C HIV-1 infection target variable regions of envelope and drive multiple pathways of viral escape
Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies
Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies
Broadly Neutralizing Antibodies for HIV Eradication
Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
Adapting Neutralizing Antibodies to Viral Variants by Structure‐Guided Affinity Maturation Using Phage Display Technology
Retracted: Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies
Non-neutralizing antibodies and vaccine-induced protection
Eliciting neutralizing antibodies with gp120 outer domain
How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin
P03-07. Autologous neutralizing antibodies that select viral escape variants emerge late after SIV infection of rhesus monkeys
Identification and characterization of broadly neutralizing antibodies targeting viral infections
P09-12. Autologous neutralizing antibodies in early subtype C HIV-1 infection target variable regions of envelope and drive multiple pathways of viral escape
Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies
Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies
Broadly Neutralizing Antibodies for HIV Eradication
Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
Adapting Neutralizing Antibodies to Viral Variants by Structure‐Guided Affinity Maturation Using Phage Display Technology
Retracted: Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies
Non-neutralizing antibodies and vaccine-induced protection
Eliciting neutralizing antibodies with gp120 outer domain